Optimizing Psoriasis Management with TYK2 Inhibitors - Episode 3
The Role of TYK2 Inhibitors in Modern Psoriasis Care
Discover how oral TYK2 inhibitors deliver targeted psoriasis control with strong safety data and biologic-like clearance, including insights on deucravacitinib and zasocitinib.
In ‘The Role of TYK2 Inhibitors in Modern Psoriasis Care,’ our panel explores the scientific advancements of TYK2 inhibition and its place as a bridge between traditional oral therapies and injectable biologics. Dr. Tina Bhutani-Jacques explains that TYK2 is a member of the Janus kinase family that facilitates signaling for key cytokines involved in psoriasis pathogenesis, such as IL-12, IL-23, and type 1 interferons. Dr. Mark Lebwohl describes how blocking these signals at the intracellular level prevents the rapid cell multiplication and epidermal thickening characteristic of the disease. He emphasizes that unlike older systemic treatments like methotrexate, which broadly suppress the immune system, TYK2 inhibitors offer a more targeted approach with fewer systemic side effects.
The experts specifically compare the first FDA approved TYK2 inhibitor, deucravacitinib, with the emerging agent zasocitinib. Dr. Lebwohl highlights that because these drugs target the regulatory domain of the TYK2 enzyme, they avoid the significant safety warnings associated with broader JAK inhibitors, such as clotting, heart attacks, and malignancy. He notes that zasocitinib shows even higher selectivity and affinity, potentially offering enhanced efficacy. Dr. Lebwohl also reflects on long term data and real-world studies presented at recent American Academy of Dermatology meetings, which confirm the effectiveness of TYK2 inhibition even in difficult to treat, overweight populations. With five years of safety data showing no significant signals for serious infections or cancers, the experts express high confidence in using these oral agents to achieve stable, long term disease control.
Our next episode, ‘Zasocitinib in Plaque Psoriasis from the LATITUDE Trials,’ features the panelists reviewing the top line results of a novel oral TYK2 inhibitor. The experts discuss how this agent achieves PASI 100 clearance rates that are comparable to injectable biologics even in refractory patient populations.
